Condition: Metastatic Pancreatic Adenocarcinoma · Sponsor: Barbara Ann Karmanos Cancer Institute
The goal of this study is to learn if the combination of nab-paclitaxel, gemcitabine and an Amplitude-Modulated Radiofrequency Electromagnetic Fields device (Therabionic P1) is safe and effective for patients with adenocarcinoma of the pancreas.
This description comes directly from the study's public registry record.
Anthony F Shields, MD PhD · 3135768734 · shieldsa@karmanos.org
Always discuss trial participation with your own doctor first.
| Karmanos Cancer Institute at McLaren Clarkston | Clarkston, Michigan, United States | Recruiting |
| Karmanos Cancer Institute | Detroit, Michigan, United States | Recruiting |
| Karmanos Cancer Institute at McLaren Flint | Flint, Michigan, United States | Recruiting |
| Karmanos Cancer Institute at McLaren Greater Lansing | Lansing, Michigan, United States | Recruiting |
| Karmanos Cancer Institute at McLaren Lapeer Region | Lapeer, Michigan, United States | Recruiting |
| Karmanos Cancer Institute at McLaren Northern Michigan, Petoskey | Petoskey, Michigan, United States | Recruiting |
| Karmanos Cancer Institute at McLaren Port Huron | Port Huron, Michigan, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06576115